Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.
Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, DI Cesare A, Panduri S, Pescitelli L, Trovato E, Prignano F. Manzo Margiotta F, et al. Among authors: ricceri f. Ital J Dermatol Venerol. 2024 Feb;159(1):64-65. doi: 10.23736/S2784-8671.23.07648-X. Epub 2023 Nov 23. Ital J Dermatol Venerol. 2024. PMID: 37997317 No abstract available.
Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
Prignano F, Pescitelli L, Trovato E, DI Cesare A, Cuccia A, Mazzatenta C, Pellegrino M, Marsili F, Castelli A, Brandini L, Niccoli MC, Taviti F, Ricceri F, Panduri S, Buggiani G, Ghilardi A, Rubegni P, Romanelli M, Pimpinelli N. Prignano F, et al. Among authors: ricceri f. Ital J Dermatol Venerol. 2022 Dec;157(6):469-479. doi: 10.23736/S2784-8671.22.07355-8. Epub 2022 Jul 5. Ital J Dermatol Venerol. 2022. PMID: 35785927 Free article.
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study.
Dragotto M, Capalbo E, Cartocci A, Manzo Margiotta F, Michelucci A, Rosi E, Ricceri F, Simoni B, Savarese I, Milanesi N, Rossari S, Magnano M, Romanelli M, Rubegni P, Prignano F, Di Cesare A, Panduri S, Pescitelli L, Trovato E. Dragotto M, et al. Among authors: ricceri f. J Eur Acad Dermatol Venereol. 2023 Apr 16. doi: 10.1111/jdv.19117. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 37062048 No abstract available.
Cutaneous hyperpigmentation induced by apremilast.
Di Cesare A, Pescitelli L, Ricceri F, Lazzeri L, Prignano F. Di Cesare A, et al. Among authors: ricceri f. Int J Dermatol. 2018 Apr;57(4):473-474. doi: 10.1111/ijd.13831. Epub 2018 Jan 19. Int J Dermatol. 2018. PMID: 29350406 No abstract available.
Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment.
Maglie R, Di Cesare A, Lazzeri L, Pescitelli L, Ricceri F, Vannucchi M, Massi D, Prignano F. Maglie R, et al. Among authors: ricceri f. Br J Dermatol. 2018 Jan;178(1):303-304. doi: 10.1111/bjd.16003. Epub 2017 Dec 29. Br J Dermatol. 2018. PMID: 28940185 No abstract available.
355 results